Cancer Immunology, Immunotherapy

, Volume 60, Issue 4, pp 525–535

Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes

  • Michael S. Leibowitz
  • Pedro A. Andrade Filho
  • Soldano Ferrone
  • Robert L. Ferris
Original Article

Abstract

Squamous cell carcinoma of the head and neck (SCCHN) cells can escape recognition by tumor antigen (TA)-specific cytotoxic T lymphocytes (CTL) by downregulation of antigen processing machinery (APM) components, such as the transporter associated with antigen processing (TAP)-1/2 heterodimer. APM component upregulation by interferon gamma (IFN-γ) restores SCCHN cell recognition and susceptibility to lysis by CTL, but the mechanism underlying TAP1/2 downregulation in SCCHN cells is not known. Because IFN-γ activates signal transducer and activator of transcription (STAT)-1, we investigated phosphorylated (p)-STAT1 as a mediator of low basal TAP1/2 expression in SCCHN cells. SCCHN cells were found to express basal total STAT1 but low to undetectable levels of activated STAT1. The association of increased pSTAT1 levels and APM components likely reflects a cause–effect relationship, since STAT1 knockdown significantly reduced both IFN-γ-mediated APM component expression and TA-specific CTL recognition of IFN-γ-treated SCCHN cells. On the other hand, since oncogenic pSTAT3 is overexpressed in SCCHN cells and was found to heterodimerize with pSTAT1, we also tested whether pSTAT3 and pSTAT1:pSTAT3 heterodimers inhibited IFN-γ-induced STAT1 activation and APM component expression. First, STAT3 activation or depletion did not affect basal or IFN-γ-induced expression of pSTAT1 and APM components or recognition of SCCHN cells by TA-specific CTL. Second, pSTAT1:pSTAT3 heterodimers did not interfere with IFN-γ-induced STAT1 binding to the TAP1 promoter or APM protein expression. These findings demonstrate that APM component downregulation is regulated primarily by an IFN-γ-pSTAT1-mediated signaling pathway, independent of oncogenic STAT3 overexpression in SCCHN cells.

Keywords

Antigen processing machinery STAT1 STAT3 Immune escape Cytotoxic T lymphocytes 

References

  1. 1.
    Cerundolo V et al (1990) Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature 345(6274):449–452PubMedCrossRefGoogle Scholar
  2. 2.
    Hosken NA, Bevan MJ (1990) Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science 248(4953):367–370PubMedCrossRefGoogle Scholar
  3. 3.
    Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27(45):5869–5885PubMedCrossRefGoogle Scholar
  4. 4.
    Seliger B (2008) Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol 5(4):361–367PubMedCrossRefGoogle Scholar
  5. 5.
    Ferris RL, Hunt JL, Ferrone S (2005) Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33(2):113–133PubMedCrossRefGoogle Scholar
  6. 6.
    Ferris RL, Whiteside TL, Ferrone S (2006) Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 12(13):3890–3895PubMedCrossRefGoogle Scholar
  7. 7.
    Lopez-Albaitero A et al (2006) Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176(6):3402–3409PubMedGoogle Scholar
  8. 8.
    Matsui M, Ikeda M, Akatsuka T (2001) High expression of HLA-A2 on an oral squamous cell carcinoma with down-regulated transporter for antigen presentation. Biochem Biophys Res Commun 280(4):1008–1014PubMedCrossRefGoogle Scholar
  9. 9.
    Meissner M et al (2005) Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 11(7):2552–2560PubMedCrossRefGoogle Scholar
  10. 10.
    Ogino T et al (2006) HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 66(18):9281–9289PubMedCrossRefGoogle Scholar
  11. 11.
    Ogino T et al (2003) Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res 9(11):4043–4051PubMedGoogle Scholar
  12. 12.
    Gough DJ et al (2008) IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 19(5–6):383–394PubMedCrossRefGoogle Scholar
  13. 13.
    Shuai K et al (1993) A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 261(5129):1744–1746PubMedCrossRefGoogle Scholar
  14. 14.
    Rouyez MC et al (2005) IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol 174(7):3948–3958PubMedGoogle Scholar
  15. 15.
    Min W, Pober JS, Johnson DR (1996) Kinetically coordinated induction of TAP1 and HLA class I by IFN-gamma: the rapid induction of TAP1 by IFN-gamma is mediated by Stat1 alpha. J Immunol 156(9):3174–3183PubMedGoogle Scholar
  16. 16.
    Chatterjee-Kishore M et al (1998) Different requirements for signal transducer and activator of transcription 1 alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem 273(26):16177–16183PubMedCrossRefGoogle Scholar
  17. 17.
    Ho HH, Ivashkiv LB (2006) Role of STAT3 in type I interferon responses. Negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281(20):14111–14118PubMedCrossRefGoogle Scholar
  18. 18.
    Thyrell L et al (2007) Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity. Exp Cell Res 313(19):4015–4024PubMedCrossRefGoogle Scholar
  19. 19.
    Murray PJ (2006) Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol 6(4):379–386PubMedCrossRefGoogle Scholar
  20. 20.
    Ito S et al (1999) Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 93(5):1456–1463PubMedGoogle Scholar
  21. 21.
    Kurte M et al (2004) A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. J Immunol 173(3):1731–1737PubMedGoogle Scholar
  22. 22.
    Petersson M et al (1998) Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 161(5):2099–2105PubMedGoogle Scholar
  23. 23.
    Salazar-Onfray F et al (1997) Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J Immunol 159(7):3195–3202PubMedGoogle Scholar
  24. 24.
    Terrazzano G et al (2000) HLA class I antigen downregulation by interleukin (IL)-10 is predominantly governed by NK-kappaB in the short term and by TAP1 + 2 in the long term. Tissue Antigens 55(4):326–332PubMedCrossRefGoogle Scholar
  25. 25.
    Chen Z et al (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5(6):1369–1379PubMedGoogle Scholar
  26. 26.
    Woods KV et al (1998) Variable expression of cytokines in human head and neck squamous cell carcinoma cell lines and consistent expression in surgical specimens. Cancer Res 58(14):3132–3141PubMedGoogle Scholar
  27. 27.
    Sriuranpong V et al (2003) Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res 63(11):2948–2956PubMedGoogle Scholar
  28. 28.
    Duffy SA et al (2008) Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113(4):750–757PubMedCrossRefGoogle Scholar
  29. 29.
    Meyer F et al (2010) Serum prognostic markers in head and neck cancer. Clin Cancer Res 16(3):1008–1015Google Scholar
  30. 30.
    Heo DS et al (1989) Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res 49(18):5167–5175PubMedGoogle Scholar
  31. 31.
    Bandoh N et al (2005) Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens 66(3):185–194PubMedCrossRefGoogle Scholar
  32. 32.
    Ogino T et al (2003) Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens 62(5):385–393PubMedCrossRefGoogle Scholar
  33. 33.
    Krutzik PO, Nolan GP (2003) Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55(2):61–70PubMedCrossRefGoogle Scholar
  34. 34.
    Andrade Filho PA et al (2010) Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients. J Immunother 33(1):83–91PubMedCrossRefGoogle Scholar
  35. 35.
    Andrade Filho PA et al (2010) CD8+ T cell recognition of polymorphic wild-type sequence p53(65–73) peptides in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 59(10):1561–1568PubMedCrossRefGoogle Scholar
  36. 36.
    Albers A et al (2005) Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65(23):11146–11155PubMedCrossRefGoogle Scholar
  37. 37.
    Lathers DM, Young MR (2004) Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine 25(5):220–228PubMedCrossRefGoogle Scholar
  38. 38.
    Lathers DM, Achille NJ, Young MR (2003) Incomplete Th2 skewing of cytokines in plasma of patients with squamous cell carcinoma of the head and neck. Hum Immunol 64(12):1160–1166PubMedCrossRefGoogle Scholar
  39. 39.
    Lui VW et al (2007) Antiproliferative mechanisms of a transcription factor decoy targeting signal transducer and activator of transcription (STAT) 3: the role of STAT1. Mol Pharmacol 71(5):1435–1443PubMedCrossRefGoogle Scholar
  40. 40.
    Zhong Z, Wen Z, Darnell JE Jr (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264(5155):95–98PubMedCrossRefGoogle Scholar
  41. 41.
    Dovhey SE, Ghosh NS, Wright KL (2000) Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res 60(20):5789–5796PubMedGoogle Scholar
  42. 42.
    Hayashi T et al (2006) The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene 25(29):4016–4026PubMedCrossRefGoogle Scholar
  43. 43.
    Setiadi AF et al (2005) Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas. Cancer Res 65(16):7485–7492PubMedCrossRefGoogle Scholar
  44. 44.
    Haque SJ et al (1997) Receptor-associated constitutive protein tyrosine phosphatase activity controls the kinase function of JAK1. Proc Natl Acad Sci U S A 94(16):8563–8568PubMedCrossRefGoogle Scholar
  45. 45.
    Baron M, Davignon JL (2008) Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2. J Immunol 181(8):5530–5536PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Michael S. Leibowitz
    • 1
  • Pedro A. Andrade Filho
    • 2
  • Soldano Ferrone
    • 1
    • 3
  • Robert L. Ferris
    • 1
    • 2
    • 3
    • 4
  1. 1.Department of ImmunologyUniversity of PittsburghPittsburghUSA
  2. 2.Department of OtolaryngologyUniversity of PittsburghPittsburghUSA
  3. 3.Cancer Immunology ProgramUniversity of Pittsburgh Cancer InstitutePittsburghUSA
  4. 4.UPCI Research PavilionThe Hillman Cancer CenterPittsburghUSA

Personalised recommendations